🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
VRTX
NASDAQ
🇺🇸 US
Vertex Pharmaceuticals
Pharmaceuticals
23Score
DipBuster Score™
$540.00
+$10.31 (+1.95%)
Live price · Source: Yahoo
52-Week Position
$403.16
87% of range
$560.25
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
BetaN/A
52W High$560.25
52W Low$403.16
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 87% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position87% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta—
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Vertex Pharmaceuticals (VRTX), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-10-20 | Brennan Daniel J. | BUY | 795 |
| 2026-09-08 | Van Grunsven Jasper | BUY | 8,682 |
| 2026-08-28 | Ambrose Kristen | BUY | 5,000 |
| 2026-08-27 | Sachs Bruce I | SELL | 6,000 |
| 2026-07-21 | Tatsis Ourania | BUY | 8,251 |
| 2026-07-21 | Sachdev Amit | BUY | 8,251 |
| 2026-07-15 | Garber Alan M | BUY | 32 |
| 2026-07-15 | Sachs Bruce I | BUY | 100 |
| 2026-07-02 | Mckechnie Duncan | SELL | 1,541 |
| 2026-07-02 | Tatsis Ourania | SELL | 1,500 |
Graham NCAV Analysis
Above net-net level
Current Assets$11.20B
Less: Total Liabilities−$6.98B
= Net Current Asset Value$4.22B
NCAV Per Share$16.6297
Current Price$540.00
Price / NCAV32.47×
Margin of Safety-3147.2%
Computed from 2025-12-31 balance sheet (Yahoo Finance). NCAV = current assets − total liabilities. Verify against the latest report.
Valuation
P/E RatioN/A
Market CapN/A
BetaN/A
Dividend/yrNone
52W High$560.25
52W Low$403.16
52-Week Range
$403.16Now$560.25
87% through annual range
From 52W High−3.6%
From 52W Low+33.9%
📖 Plain English Summary
Vertex Pharmaceuticals is at 87% of its 52-week range.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for VRTX
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — VRTX
Heuristic · balance sheet, insider filings, price data, academic research
Vertex Pharmaceuticals — DipBuster Score 23/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Vertex Pharmaceuticals free
Add VRTX to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Freetrade
Simple investing app. Free ISA. UK and US stocks. FCA regulated.
Free share when you fund your account
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
5/25
Momentum & Volume
13/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
1
/100 · NEUTRAL
dip depth
1/25
oversold rsi
0/25
mean reversion
0/15
insider zone
0/25
capitulation
0/10
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 23/100
📈
Strong recent momentum — price and volume trending in the right direction.